

In re: Whitehouse  
Appl. No. 09/802,365  
Filed: March 9, 2001  
Page 2 of 11

*Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403. BLAST-nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding the polypeptide of interest. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to the polypeptide of interest. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389. Alternatively, PSI-Blast can be used to perform an iterated search that detects distant relationships between molecules. See Altschul *et al.* (1997) *supra*. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See the website at [ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov). Also see the ALIGN program (Dayhoff (1978) in *Atlas of Protein Sequence and Structure* 5:Suppl. 3 (National Biomedical Research Foundation, Washington, D.C.) and programs in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, Wisconsin), for example, the GAP program, where default parameters of the programs are utilized.

Please amend the abstract at page 29 to read as follows:

Compositions and methods for improving erectile function in a patient are provided.

Compositions comprise one or more angiogenic agents or growth factors. Such agents or growth factors are administered in therapeutically effective amounts to treat or prevent erectile dysfunction. Pharmaceutical compositions comprising a therapeutically effective amount of at least one angiogenic agent or growth factor and a pharmaceutically acceptable carrier are also provided. The methods of the invention to improve erectile function and treat erectile dysfunction comprise administering at least a single unit dose of a pharmaceutical composition comprising the angiogenic agent or growth factor, generally at a local target site in the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.